title: In vitro evaluation of combination drug purging for autologous bone marrow transplantation.
abstract: Using an in vitro model, we studied whether combining 4-hydroperoxycyclophosphamide (4HC) with other drugs could improve its effectiveness as an ex vivo purging agent for autologous bone marrow transplantation. 4HC was incubated simultaneously with vincristine and etoposide, and sequentially with methylprednisolone, in various combinations. Compared to 4HC alone, all drug combinations increased the kill of the leukemia cell lines K562 and CEM without increasing the kill of granulocyte-macrophage colony-forming units (CFU-GM). The combination of 4HC, vincristine and methylprednisolone was the most active, and this drug combination was also the only combination which showed improved selective cytotoxicity (compared to 4HC alone) toward REH cells. This combination inhibited at least 8 logs of clonogenic leukemia cells from all three cell lines at doses which spared 1% of CFU-GM. This was an increase of 1.7 to 6.6 logs of clonogenic leukemia cell kill over 4HC alone. This drug combination displayed similar differential activity between fresh clonogenic leukemia cells and CFU-GM cultured from the bone marrows of seven patients about to undergo autologous bone marrow transplantation for acute lymphocytic leukemia.
authors.affiliation: Johns Hopkins Oncology Center, Johns Hopkins Medical Institutions, Baltimore, MD 21205.
authors.forename: R J
authors.initials: RJ
authors.lastname: Jones
authors.forename: C B
authors.initials: CB
authors.lastname: Miller
authors.forename: B A
authors.initials: BA
authors.lastname: Zehnbauer
authors.forename: S D
authors.initials: SD
authors.lastname: Rowley
authors.forename: O M
authors.initials: OM
authors.lastname: Colvin
authors.forename: L L
authors.initials: LL
authors.lastname: Sensenbrenner
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D016026:Bone Marrow Transplantation; D002470:Cell Survival / Q000187:drug effects; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000031:analogs & derivatives* / Q000494:pharmacology; D005047:Etoposide / Q000494:pharmacology; D006801:Humans; D008775:Methylprednisolone / Q000494:pharmacology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D014182:Transplantation, Autologous; D014407:Tumor Cells, Cultured; D014410:Tumor Stem Cell Assay; D014750:Vincristine / Q000494:pharmacology
chemical_list: D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; C011272:perfosfamide; D008775:Methylprednisolone